

January 19, 2010

AlphaVax Advances Filovirus Biodefense Vaccines. Under existing grant support from the NIH, AlphaVax has completed the manufacture, testing and release assays of GMP-compliant clinical trial material for a filovirus vaccine candidate at its pilot facility in Lenoir, North Carolina. Further development to advance a multivalent vaccine against Marburg and Ebola viruses into clinical testing is currently under review. Such development will include consideration of the Request for Information (RFI) released by the U.S. Army on January 15, 2010, under which the Department of Defense is seeking companies with the experience and capability to advance Filovirus Vaccine(s) to Food and Drug Administration (FDA) Approval.

Filoviruses are a group of viruses known for causing concentrated outbreaks of hemorrhagic fever disease that is very often fatal. Two well known viruses in this group are Marburg and Ebola. Pre-clinical development of vaccines for both Marburg and Ebola was performed in collaboration with the US Army Medical Research Institute for Infectious Diseases (USAMRIID) at Fort Detrick, MD, which has appropriate facilities for testing vaccines against these deadly viruses. Studies of AlphaVax's vaccines at USAMRIID have demonstrated that single dose vaccination of non-human primates with an alphavirus replicon particle vaccine expressing Marburg or Ebola glycoprotein can protect against lethal dose challenge with Marburg or Ebola virus. A summary presentation of the results can be viewed here: ['Alphavirus Replicon Vaccines for Marburg and Ebola Viruses'](#)